Sun Pharmaceutical Industries Limited has reported strong financial results for the quarter and year ended March 31, 2026. The company achieved consolidated full-year sales of ₹582,201 million, representing an 11.9% year-on-year growth. Net profit for the full year reached ₹114,794 million. Driven by growth in innovative medicines, the company maintains a robust balance sheet and continues to solidify its global presence.
Full-Year Financial Performance
Sun Pharma delivered a strong performance in FY26, with consolidated sales increasing by 11.9% to reach ₹582,201 million. The company’s EBITDA for the year grew by 16.1%, standing at ₹177,314 million with a healthy EBITDA margin of 30.3%. Full-year net profit rose to ₹114,794 million, up 5.0% compared to the previous year. R&D investments remained a strategic priority, totaling ₹35,540 million, or 6.1% of sales.
Fourth Quarter Highlights
For the fourth quarter ended March 31, 2026, the company reported sales of ₹145,598 million, a 13.6% growth over the same period last year. Quarterly net profit demonstrated significant momentum, rising by 26.2% to ₹27,140 million. EBITDA for the quarter was recorded at ₹39,542 million, with an EBITDA margin of 27.1%.
Segment and Strategic Growth
The company’s focus on Innovative Medicines continues to drive its global strategy. In the U.S. market, innovative medicine revenues surpassed the USD 1 billion milestone for the year. Furthermore, the company reported a strong performance in India, where formulation sales grew by 14.8% in the fourth quarter, reaching ₹48,359 million. Sun Pharma also achieved a 0.3 percentage point market share gain in India, the highest since the Ranbaxy acquisition.
Dividend and Corporate Developments
Reflecting its commitment to shareholder value, the Board has recommended a final dividend of ₹5.00 per equity share for the year FY26. This follows an interim dividend of ₹11.00 per share, bringing the total dividend for the year to ₹16.00 per share. Additionally, the company is progressing with its strategic acquisition of Organon & Co., which is expected to further accelerate its transformation into a leading global pharmaceutical entity.
Source: BSE
